DICE Therapeutics
Ms. Sharon Tetlow brings 30 years of financial leadership to DICE Therapeutics. She currently serves as boardmember and audit committee chair at Catalyst Biosciences (NASDAQ: CBIO) and as a supervisory board member and chair of the audit committee at Valneva SE (NASDAQ: VALN; Euronext Paris: VAL.PA). She has led Potrero Hill Advisors, a life-sciences focused provider of financial strategy and operational services since January 2016, and prior to Potrero was managing director of Danforth Advisors. For more than 15 years before that, Ms. Tetlow served as CFO of various biotech companies, both private and public. Ms. Tetlow was previously on the board of directors, audit committee and transaction committee of Armetheon, Inc., a privately held biotech company. Ms. Tetlow holds a B.A. in Psychology from University of Delaware and an M.B.A. from the GSB at Stanford University.
This person is not in the org chart
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.